• Eli Lilly is trading 5.3% up at $1,175.00 in pre-market after reporting second-quarter 2026 financial results that exceeded analyst expectations.
  • The pharmaceutical giant also raised its full-year revenue guidance, reinforcing investor confidence in its dominant position in the incretin market and expanding obesity drug pipeline.
  • The company recently announced an expansion of early access to its experimental obesity drug retatrutide, further contributing to investor enthusiasm.